Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.
5/1/2014 J Transl Med. 2014 May 13;12:127. Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH. Interleukin-2 (IL-2) therapy has been demonstrated to induce responses in 10-20% of advanced melanoma and renal cell carcinoma patients, which translates into durable remissions in up…
